复方菝葜颗粒联合PT新辅助化疗方案对晚期宫颈癌的疗效探讨

目的:研究复方菝葜颗粒联合PT新辅助化疗方案对晚期宫颈癌的疗效。方法:选择2013年1月～2016年12月我院收治的63例晚期宫颈癌患者,随机分为两组。对照组使用PT新辅助化疗方案,其中顺铂的剂量为75 mg/m2,紫杉醇为的剂量为175 mg/m2;观察组联合口服复方菝葜颗粒,每次3次,每次服用1袋。两组均连续治疗1个月,然后进行广泛性手术治疗。治疗前后,比较两组的瘤体最大直径和免疫功能指标;并记录患者的远期生存情况。结果:治疗后,观察组的有效率为80.64%,明显高于对照组(56.25%,P0.05);两组的瘤体最大直径均较治疗前明显降低(P0.05),且观察组宫颈癌患者的瘤体最大直径明显低于对照组(P0.05);对照组的CD_3~+、CD_4~+、IgM、IgA、IgG较治疗前明显降低(P0.05),观察组的CD_3~+、CD_4~+、IgM、IgA、IgG较治疗前明显升高(P0.05),且观察组CD_3~+、CD_4~+、Ig M、Ig A、Ig G明显高于对照组(P0.05);观察组1年生存率为93.55%(29/31)、2年生存率为83.87%(26/31)、3年生存率为77.42%(24/31),均明显高于对照组(P0.05)。结论:复方菝葜颗粒联合PT新辅助化疗方案能改善晚期宫颈癌患者的免疫功能,提高远期生存率。

A Study on the Effect of Compound Smilax Granule Combined with Pt Neoadjuvant Chemotherapy on the Advanced Cervical Cancer

ABSTRACT Objective: To investigate the effect of compound Smilax granule combined with Pt neoadjuvant chemotherapy on the advanced cervical cancer. Methods: 63 cases of patients with advanced cervical cancer who were treated in our hospital from January 2013 to December 2016, were selected and divided into two groups randomly. The control group was given Pt neoadjuvant chemotherapy, the dose of cisplatin was 75 mg/m², the dose of paclitaxel was 175 mg/m². The observation group was treated by compound Smilax granules three times a time, one bag a time. Both groups were treated continuously for 1 month. Then they were given extensive surgical treatment. Before and after treatment, the tumor diameter and immune function indexes of the two groups were compared, and the long-term survival of patients was recorded. Results: After treatment, he effective rate of observation group was 80.64 %, which was significantly higher than control group (56.25 %, P<0.05). After treatment, the maximum diameter of tumor in the two groups were significantly decreased (P<0.05), which was significantly lower in the observation groupthan that in the control group (P<0.05). After treatment, the CD3⁺, CD4⁺, IgM, IgA and IgG in the control group were significantly lower (P<0.05), and the CD3⁺, CD4⁺, IgM, IgA and IgG in the observation group were significantly higher (P<0.05), and the CD3⁺, CD4⁺, IgM, IgA and IgG in the observation group were significantly higher than those in the control group (P<0.05). The 1-year survival rate of the observation group was 93.55 % (29/31), the 2-year survival rate was 83.87 % (26/31), the 3-year survival rate was 77.42 % (24/31), which were all significantly higher than that of the control group (P<0.05). Conclusion: Compound Smilax granule combined with Pt neoadjuvant chemotherapy can improve the immune function and long-term survival rate of patients with advanced cervical cancer.